

Pertussis: Current Outbreak Trends and Vaccination **Strategies**



Ģ

Illinois State Medical Society

The Illinois Chapter, American Academy of Pediatrics designates each live webinar for a maximum of 1 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses and Nurse Practitioners can submit Certificates of Attendance to their accrediting board to claim credit for participation in the live webinars.

CME Accreditation Statement



Disclosure Grid



Name and Credentials	Role in Activity	Was there a relevant Financial Disclosu	ro List of Mitigated Disclosures	
	Planning Committee Member	No	N/A	
Carissa Lee Holmes,MD	Planning Committee Member	NO	N/A	
Anita Chandra-Puri, MD, FAAP	Planning Committee Member	Yes	Consiting Fees - Merck; Speakers Bureau - GSK	
Shoji Samson, DO	Planning Committee Member	No	N/A	
Ayezah Mir,MD	Planning Committee Member	No	N/A	
Lilly Immergluck, MD	Faculty/Presenter	Yes	 Consulting Fees - Scientific advisory board for North America- Moderna 2. Contract Research -University of Chicago receives funds for me to conduct research from Moderna, Sanofi, and Pfizer. Morehouse School of Medicine received funds for me to conduct research from Merck, GSK, Novavax, Moderna, Pfizer, Affinivix, and Melinta 3. Advisory Board - Executive Advisory Board for American Academy of Pediatrics, Section on Infectious Diseases Funded by Pediatric Emergency Medicine Associates, LLC 	
Rutu Ezhuthachan MD	Planning Committee Member	No	N/A	
Caroline Werenskjold, MPH	Staff	No	N/A	
Monica Del Ciello, MPH	Staff	No	N/A	
Craig Batterman, MD	Planning Committee Member	No	N/A	
Brandi Vogt, CHES	Staff	No	N/A	
	Staff			
Magale Avitia, MPH, CHES	Moderator/Facilitator	No	N/A	
Sharon Hovey, MD	Planning Committee Member	No	N/A	
Shefali Parikh	Staff	No	N/A	
Nina Alfieri MD	Planning Committee Member	No	N/A	
Stephanie Atella, MPH, CHES	Staff	No	N/A	
Erin Moore, MS	Staff	No	N/A	
Wayne Franklin, MD	CME Reviewer	No	N/A	
Joe Hageman, MD	CME Reviewer	Yes	Royalties- Owlet Inc	
Alexandra Arca	Staff	No	N/A	





Lilly Immergluck, MD, MS, FAAP

Professor of Pediatrics at the University of Chicago Director, Vaccine Center of Excellence, University of Chicago

https://biologicalsciences.uchicago.edu/faculty/lilly-immergluck

Disclosures



- University of Chicago receives funds for me to conduct research from Moderna, Sanofi, and Pfizer.
- In the past <u>24 months</u>, Morehouse School of Medicine received funds for me to conduct research from Merck, GSK, Novavax, Moderna, Pfizer, Affinivix, and Melinta
- Executive Advisory Board for American Academy of Pediatrics, Section on Infectious Diseases
- Scientific advisory board for North America- Moderna
- Funded by Pediatric Emergency Medicine Associates, LLC (through 2023)

Learning Objectives

As a result of attending this webinar, participants will be able to:

Understand the clinical features and symptoms of pertussis disease.

02

Summarize the latest information regarding the ongoing pertussis outbreak in U.S. and Illinois.

03

01

Identify the latest versions of pertussis-containing vaccines.



Describe the current recommendations for vaccinations against pertussis

What is Pertussis?




- Pertussis also known as Whooping Cough is caused by a type of bacteria called Bordetella pertussis (fastidious, gram negative, pleomorphic bacillus).
- Humans are only known hosts.
- Transmission is usually person to person through respiratory droplets or contact with airborne droplets; occurs year-round.
- Anyone, but especially infants and young children, may experience serious and potentially life-threatening complications from pertussis.
 - In 2018, pertussis incidence per 100,000 was 72.3 in infants younger than age 6 months and 32.7 in infants aged 6 to 12 months.

Pertussis Clinical Features

- Incubation period: 7 through 10 days (range, 4 through 21 days)
- **Catarrhal stage**: Insidious onset of coryza (runny nose), sneezing, and a mild cough, similar to the common cold.
 - o 1-2 weeks
- **Paroxysmal stage**: More severe cough and may experience paroxysms of numerous, rapid coughs, and the classic whoop occurs. Usually when the diagnosis of pertussis is suspected.
 - o 1-6 weeks
- Convalescence stage: Gradual recovery
 - o Weeks to months

Note: Factors influencing length of communicability: age, immunization status or previous infection and receipt of appropriate antibiotic therapy



Whooping Cough (Pertussis)



Transmission of Pertussis




- Vaccination immunity wanes over time (more pronounced if acellular vaccine used for entire prime/boost series)
 - ~80% of household contacts previously immunized in infants symptomatic were infected (classic pertussis to mild cough)
 - Natural immunity also wanes over time
 - Pertussis cases likely increase both in unvaccinated and vaccinated populations
- Most contagious: during catarrhal through ~3rd week after onset of paroxysms.
 - Factors influencing length of communicability: age, immunization status or previous infection and receipt of appropriate antibiotic therapy

How does Pertussis spread?

The bacteria that cause whooping cough spread easily from person to person through the air, especially those in close contact.

Examples of close contact:

- 1. Living in the same household.
- 2. Sneezing or coughing.
- 3. Spending a lot of time close together in schools and daycares.






Treatment of Pertussis



- Treatment: administering during catarrhal stage may 'ameliorate' disease
 - 5-day course of azithromycin for treatment and for postexposure prophylaxis (PEP)
 - After paroxysmal cough, no discernible effect on course of illness (but recommended to limit spread of organisms to others)
 - Rare reports of resistance to azithromycin
 - Alternative: TMP-SMX- for patients > 2 moths who cannot tolerate or infected with macrolide-resistant strain
- Isolation: 21 days from onset of cough if appropriate antimicrobial therapy is not administered or for 5 days after initiation of effective therapy





Epidemiology of Pertussis

Current Outbreak





Surveillance of Pertussis, 2024

- CDC tracks pertussis cases using national surveillance network
 - Emerging Infections Program (EIP): CDC partners with seven states participating in the EIP-network. (Surveillance includes other *Bordetella* species)
 - National Notifiable Diseases Surveillance System (NNDSS).
 - Weekly cases of selected infectious national notifiable diseases, from the NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published weekly in alphabetical order by condition.

Ģ

Epidemiology in the United States

- In **2018**, pertussis incidence per 100,000 was 72.3 in infants younger than age 6 months and 32.7 in infants aged 6 to 12 months.
- In 2024, reported cases of pertussis increased across the United States
- The number of reported cases this year (2024) is <u>higher</u> than what was seen at the same time in 2019, prior to the pandemic.
 - During the pandemic (e.g., masking, remote learning)likely lowered transmission of pertussis.
- Preliminary data show that more than five times as many cases have been reported as of week 43, reported on <u>October 26, 2024</u>, compared to the same time in <u>2023</u>

Top States with most cases (October 16, 2024)

		Pertussis					
Reporting Area		Current week	Previous 52 weeks Max +		Cum YTD 2024 †	Cum YTD 2023 †	
U.S. Residents, excluding U.S. Territories		462	817		20,791	4,559	
New England		8		51	841	57	
Connecticut		-		8	29	4	
Maine		8		11	110	39	
Massachusetts				34	541	10	
New Hampshire	In 2024,	Illinois rai	1ks #3	5	28	3	
Rhode Island	for highest number			6	68		
Vermont	Ŭ		12	65			
/liddle Atlantic	cases YT	D across t	he U.S.	190	4,847	997	
New Jersey		-		37	423	193	
New York (excluding New York City)		42	97		1,326	278	
New York City		-		38	735	29 [°]	
Pennsylvania		43		107	2,363	235	
ast North China a		126		238	4,722	1.237	
Illinois		-		54	1,356	428	
Inglana		-		17	255	114	
Michigan		4		42	652	7'	
Ohio		88		92	1,032	58	
Wisconsin		34		111	1,434	35	
Vest North Central		36		61	1,169	246	
lowa		-		18	155	50	
Kansas		-		12	144	52	



Total Cum 2023 (Week 52): 4,589




Accessed: 11.5.2024: https://wonder.cdc.gov//nndss/static/2024/43/2024-43-table990.html)

Ģ

U.S. Distribution of Pertussis Cases

 Widespread use of the vaccine began with the introduction of the diphtheria, tetanus toxoid, and whole-cell pertussis (DTP) vaccine in 1948. Since then, the number of cases each year has decreased more than 90%, compared with the pre-vaccine era.


Reported NNDSS pertussis cases: 1922-2022



Illinois (9.26.2024)




• 1,087 confirmed and probable cases of pertussis reported in Illinois in 2024.



Chicago (10.1.2024)




- A total of **217** cases among Chicagoans have been reported in 2024 as of October 1.
 - **3.5 increase in cases** compared to the same time period in 2023 and is the highest total in the last 6 years



Chicago (cont.)




- Incidence rates have been highest among young children ages 0 to 4 years followed by schoolage children 5 to 17 years.
- Nineteen cases have been among infants less than 1 year of age who are at highest risk for severe pertussis outcomes.



Chicago (cont.)

 Cases have been reported in ZIP Codes across Chicago, but most have been among residents of the northside of Chicago.






Chicago - Pertussis

- Most cases have been mild,
- 13 (6%) of cases were hospitalized
- 26 (12%) visited the emergency room
- Four outbreaks have been identified this year:
 - School settings (N=3)
 - Childcare center (N=1)
- Demographic Race-Ethnicity:
 - White (Non-Latinx)- (63%) followed by
 - Latinx (21%), 7% among
 - Asian, non-Hispanic (7%)
 - Black, Non-Latinx (5%)

Reporting of Pertussis in Chicago



- **Chicago**: Pertussis cases should be reported electronically to CDPH within 24 hours through I-NEDSS.
 - Outpatient providers without an I-NEDSS account may report via CDPH's secure online report form: <u>https://redcap.link/ChicagoVPDReport</u>.
- Illinois: Schools and healthcare providers should notify their local health department if they become aware of a suspected or confirmed case of pertussis in both students, patients, or staff within 24 hours of diagnosis.





Vaccination



About The Vaccines Against Pertussis

Ģ

- DTaP (in children who received 5 shots), protection against disease:
- Nearly all children (98 in 100) <u>within a year of</u> the last shot.
- About 7 in 10 children <u>five years after getting</u> the last DTaP shot.
 - The other 3 in 10 children are partially protected. (so, if illness, less severe form)

- Tdap (1 booster, in protection against disease):
 - 7 in 10 people in the <u>first year after</u> getting it.
 - 3 or 4 in 10 people <u>four years after</u> getting it.
- Women get Tdap during pregnancy, the vaccine protects:
 - More than 3 in 4 babies younger than 2 months old from whooping cough.
 - About 9 in 10 babies from being hospitalized from whooping cough.

Vaccination Immunity




- Vaccination immunity wanes over time (more pronounced if acellular vaccine used for entire prime/boost series)
 - ~80% of household contacts previously immunized in infants symptomatic were infected (classic pertussis to mild cough)
 - Natural immunity also wanes over time
 - Pertussis cases likely increase both in unvaccinated and vaccinated populations

Ģ

Vaccinations Declining

- Decrease in school vaccination coverage over time
- For 2022-23 school year, Illinois school protection % ranged from 88.84% 99.52% across all counties



https://dph.illinois.gov/topics-services/prevention-wellness/immunization/coverage-dashboards/school-vaccination-coverage-dashboard.html

Vaccination - DTaP/Tdap



- DTaP: 5-dose series (3-dose primary series at age 2, 4, and 6 months, followed by a booster doses at ages 15–18 months and 4–6 years)
 - Prospectively: Dose 4 may be administered as early as age 12 months if at least 6 months have elapsed since dose 3
 - Retrospectively: A 4th dose that was inadvertently administered as early as age 12 months may be counted if at least 4 months have elapsed since dose 3
- Tdap: Age 11–12 years: 1 dose Tdap (adolescent booster)
- Pregnant people need a Tdap booster each pregnancy
- Catch-Up Vaccination:
 - DTaP: Dose 5 is not necessary if dose 4 was administered at age 4 years or older and at least 6 months after dose 3
 - Tdap: Dependent on age and DTaP vaccination history

People of WHOOPING COUGH VACCINES Tdap DTaP Tdap Tdap for young children for adults for preteens for pregnant women 2, 4, and 6 months ✓ During the ✓ 11 through ✓ Anytime for those who 15 through 18 months have never received it 27-36th week of 12 years 4 through 6 years each pregnancy www.cdc.gov/whoopingcough



Illinois School Requirements

- For children enrolling in a childcare facility, preschool, early childhood or pre-kindergarten program: Three doses of diphtheria, tetanus, pertussis (DTP or DTaP) by 1 year of age, and one additional dose by the second birthday.
- For children entering kindergarten or first grade: Four or more doses of diphtheria, tetanus, pertussis (DTP or DTaP) vaccine with the last dose being a booster and having been received on or after the fourth birthday.
- For children entering sixth grade: one dose Tdap vaccine at age ≥11 years, regardless of interval since the last dose of DTP, DTaP, or Td.

Vaccine Confidence



- Includes the trust that patients, their families, and providers have in:
 - Recommended vaccines.
 - Providers who administer the vaccines.
 - The processes and policies that lead to vaccine development, licensure, or authorization.
 - Manufacturing.
 - Recommendations for use.

Health literacy is important!



Increasing Vaccine Confidence

- Take time to walk through complicated concepts what do new terms mean and why do they matter.
- Make a strong recommendation for routinely recommended vaccines and immunizations.
- Discuss why regular vaccinations are important.
- Take time to respond to questions and concerns.
- Educate and encourage; use motivational interviewing.



Reminder Recall



- Strategies can include social media, patient portal communications, texts and phone calls, or auto-dialers.
- Sample messages:
 - Needing Catch-up vaccine: [PRACTICE NAME] is contacting you as our records indicate that your child is overdue for a vaccine. Please call [PRACTICE PHONE NUMBER] today to schedule your child's vaccination.
 - Routine, on-time vaccinations: "Hi! [Practice Name] is offering a friendly reminder that your child's wellness visit and/or vaccinations are due. It is very important to stay on track with these appointments. Please call our office at [PRACTICE PHONE NUMBER] to schedule your child's appointment. See you soon!"
 - More information on <u>Reminder and Recall</u> strategies.

Resources

- Immunize.org's Pertussis Clinical Resources
- <u>CDC Manual for the Surveillance of Vaccine-Preventable</u> <u>Diseases: Pertussis</u>
- <u>CDPH Pertussis in Schools</u> Webpage
- <u>https://www.cdc.gov/acip-recs/hcp/vaccine-specific/dtap-tdap-td.html</u>
- <u>https://www.cdc.gov/pertussis/php/surveillance/</u>
- Centers for Disease Control and Prevention. National Notifiable Diseases Surveillance System, Weekly Tables of Infectious Disease Data. Atlanta, GA. Office of Public Health Data, Surveillance, and Technology. Available at: <u>https://www.cdc.gov/nndss/data-statistics/index.html</u>.

She thinks **"Pertussis"** is something you play in music class.

Childhood vaccinations keep it that way

Pertussis isn't a drum, it's a very contagious bacterial infection of the lungs. Also known as whooping cough, pertussis can cause pneumonia, seizures, and brain damage. Childhood vaccinations continue to help protect kids from pertussis. Let's keep it that way.

Talk to your child's healthcare provider about keeping up to date with childhood vaccinations.

Thanks!

Questions?







Upcoming Events

Immunizations Webinar – AAP Immunizations Update and Best Practices from Other States Wednesday, December 4th at 12pm CT

Register at illinoisaap.org/upcoming-events or scan the QR code:



